Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Study of the activity of PD-1 inhibitors in metastatic uveal melanoma
The aim of the research is to study the activity of PD-1 inhibitors in patients with metastatic uveal melanoma and treated by Nivolumab and Pembrolizumab. These molecules have already received the authorities approvals. The data collected will be crucial for the understanding of the mechanism of PD-1 inhibitors and also for the futures studies.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Response rate Data collection of the efficacity of PD-1 inhibitors | Description of Response rate | December 2019 |
| Progression Free Survival Data collection of the efficacity of PD-1 inhibitors | Description of PFS (Progression Free Survival) | December 2019 |
| Global Survival Data collection of the efficacity of PD-1 inhibitors | Description of Global Survival | December 2019 |
| Stability Data collection of the efficacity of PD-1 inhibitors | Description of Stability at 6 months | December 2019 |
| Objective response Data collection of the efficacity of PD-1 inhibitors | Description of Objective response | December 2019 |
| Measure | Description | Time Frame |
|---|---|---|
| Exploration of PD-1 inhibitors biomarkers | The study of PD-1 inhibitors biomarkers could be useful to identify a group of patients whose the molecules are most activated and then for futures studies. | December 2019 |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Patients with metastatic uveal melanoma.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Manuel Rodrigues, MD | Institut Curie | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Rodrigues | Paris | Île-de-France Region | 75005 | France |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 35863105 | Result | Saint-Ghislain M, Derrien AC, Geoffrois L, Gastaud L, Lesimple T, Negrier S, Penel N, Kurtz JE, Le Corre Y, Dutriaux C, Gardrat S, Barnhill R, Matet A, Cassoux N, Houy A, Ramtohul T, Servois V, Mariani P, Piperno-Neumann S, Stern MH, Rodrigues M. MBD4 deficiency is predictive of response to immune checkpoint inhibitors in metastatic uveal melanoma patients. Eur J Cancer. 2022 Sep;173:105-112. doi: 10.1016/j.ejca.2022.06.033. Epub 2022 Jul 19. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000098943 | Uveal Melanoma |
| ID | Term |
|---|---|
| D008545 | Melanoma |
| D018358 | Neuroendocrine Tumors |
| D017599 | Neuroectodermal Tumors |
| D009373 | Neoplasms, Germ Cell and Embryonal |
Not provided
Not provided
Not provided
Not provided
Not provided
Biocollection of tumoral tissues
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
| D009380 | Neoplasms, Nerve Tissue |
| D018326 | Nevi and Melanomas |
| D014604 | Uveal Neoplasms |
| D005134 | Eye Neoplasms |
| D009371 | Neoplasms by Site |
| D005128 | Eye Diseases |
| D014603 | Uveal Diseases |